U.S. Food and Drug Administration approved Farxiga (dapagliflozin) for global congestive heart failure drugs market

 

Congestive Heart Failure Drugs Market

Robust pipeline of drugs under development for congestive heart failure is propelling the growth of the congestive heart failure drugs market. Moreover, the growing approval of new drugs from the Food and Drug Administration (FDA) is again expected to augment the growth of the congestive heart failure drugs market. For instance, in February 2021, Novartis announced that the US Food and Drug Administration (FDA) has approved the following expanded indication for Entresto® (sacubitril/valsartan): to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure1.

On other hand, lack of awareness and diagnosis rate for the disease such as hypertension which is a major cause of heart failure is acting as a restraint in the global congestive heart failure drugs market. According to a study published in NCBI in 2013, only 49% of patients suffering from hypertension were aware of the diagnosis in high-income countries, and this percentage (i.e. 40.8%) was even lower in low-income countries

North America is expected to gain significant growth over the forecast period and this is attributed to the high prevalence rate of heart disease and also the continuous launch of new products in the region. According to the U.S. Department of Health & Human Services, about 6.2 million adults in the United States have heart failure. In 2018, heart failure was mentioned on 379,800 death certificates (13.4%).

1.      In May 2020, the U.S. Food and Drug Administration approved Farxiga (dapagliflozin) oral tablets for adults with heart failure with reduced ejection fraction to reduce the risk of cardiovascular death and hospitalization for heart failure.

2.      In January 2021, Merck & Co. and Bayer won Food and Drug Administration approval for the heart failure drug Verquvo, one of the few medicines Merck has recently brought through late-stage development

3.      In May 2020, Amgen and Cytokinetics, Incorporated announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for omecamtiv mecarbil, being developed for the potential treatment of chronic heart failure with reduced ejection fraction (HFrEF).

Congestive Heart Failure (CHF) is a condition where the heart does not circulate enough oxygenated blood throughout the body due to inadequate coronary blood flow. Left-sided CHF describes a heart condition wherein the heart pump moves the oxygen-rich blood into the right atrium, then to the left side, and back down to the right ventricle. The right ventricle pumps most of the cardiovascular force, so it is larger than the left ventricle and vital for proper cardiac function. This allows the heart muscle to work harder, raising blood pressure, which can cause fainting, dizziness, or shock if the ventricular pressure is too high.


Comments

Popular posts from this blog

Fitness Equipment Market is doing warm-ups to pull growth-rich opportunities from the growing obesity rates accompanied by the sedentary lifestyles

Botanical and Plant Derived Drugs Market by Source,Dosage - Global Industry Analysis,Size,Share

Pressure Bandages Market : Global Industry Analysis and Opportunity Assessment